Progress on RNAi-based molecular medicines

被引：29

作者：

Chen, Jing ^{[1
]}

Xie, Jianping ^{[1
]}

机构：

[1] Southwest Univ, Inst Modern Biopharmaceut, Minist Educ Ecoenvironm Gorges Reservoir Reg 3, State Key Lab Breeding Base,Sch Life Sci, Chongqing 400715, Peoples R China

来源：

INTERNATIONAL JOURNAL OF NANOMEDICINE | 2012年 / 7卷

关键词：

RNA interference; delivery systems; liposome; nanoparticle; molecular medicines; SMALL INTERFERING RNA; DOUBLE-STRANDED-RNA; GOLD NANOPARTICLES; MESSENGER-RNA; MAMMALIAN-CELLS; CANCER-CELLS; SEQUENCE REQUIREMENT; LENTIVIRAL VECTORS; TRANSGENIC MICE; SIRNA DELIVERY;

D O I：

10.2147/IJN.S31897

中图分类号：

TB3 [工程材料学];

学科分类号：

082905 [生物质能源与材料];

摘要：

RNA interference (RNAi) is a promising strategy to suppress the expression of disease-relevant genes and induce post-transcriptional gene silencing. Their simplicity and stability endow RNAi with great advantages in molecular medicine. Several RNAi-based drugs are in various stages of clinical investigation. This review summarizes the ongoing research endeavors on RNAi in molecular medicine, delivery systems for RNAi-based drugs, and a compendium of RNAi drugs in different stages of clinical development. Of special interest are RNAi-based drug target discovery and validation, delivery systems for RNAi-based drugs, such as nanoparticles, rabies virus protein-based vehicles, and bacteriophages for RNA packaging.

引用

页码：3971 / 3980

页数：10

共 113 条

[1]

Pharmacological Characterization of Chemically Synthesized Monomeric phi29 pRNA Nanoparticles for Systemic Delivery [J].